The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of ...

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year ...

Catalent is laying off 350 employees in its gene therapy manufacturing division in Baltimore “due to an unexpected shift in ...

Sarepta and its gene therapy drug Elevidys were the target of 37 Freedom of Information Act requests during the first seven months of 2025, according to PoliScio Analytics’ competitive-intelligence ...

Learn more about whether ADMA Biologics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...